In This Article:
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.
A committee of clinical trial monitors has advised Pliant Therapeutics to stop giving its experimental fibrosis drug to patients in a Phase 2 trial, seeding doubt about the therapy’s future.
Pliant said in a short statement late Friday that, following a routine data check by the committee, the company has voluntarily stopped enrolling and dosing patients with its drug, bexotegrast, in a Phase 2b/3 trial in idiopathic pulmonary fibrosis.
Pliant didn’t say whether the trial was stopped due to safety concerns or its drug being ineffective — two reasons an independent data committee might call for a pause in dosing. The company is currently reviewing data “to understand the [committee’s] rationale,” it said, and will keep the study blinded “to preserve trial integrity.”
Current study volunteers will remain in the trial and be monitored while the review is underway. In the meantime, though, the company has informed investigators of the data board’s decision and is in the process of disclosing the news to global health regulators.
The announcement, and lack of specific details involved, took investors and Wall Street analysts by surprise. “This is a unique situation that we (and most investors we have spoken to) have never seen before,” wrote Leerink Partners analyst Faisal Khurshid, in a research note on Sunday.
Without those details, Khurshid, and other analysts following the company, were left to speculate what might have triggered the trial monitors’ decision. An independent data safety monitoring board periodically evaluates safety and efficacy data throughout a clinical trial. The committee also follows certain guidelines, one of which is to recommend a company immediately unblind and stop a trial because an experimental treatment is clearly unsafe or ineffective.
Notably, in Pliant’s case, Khurshid wrote, the dosing halt is voluntary and the study is still blinded. That could mean data reviewers “saw something that gave enough concern” to stop treating patients, but not enough to end the study altogether, he wrote.
“Our understanding is [Pliant] management does not know the exact findings,” he added, “which seems like an impasse” because Pliant would have to choose between unblinding the study and losing its progress, or trying to resolve the issue while keeping the trial intact.